A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: urban (3), residential (24), industrial (50)

Specialty research lead advertisement Surgery May 2022.docx

Description
Clinical Research Specialty Lead - advertisement The National Institute for Health and Care Research (NIHR) is funded through the Department
Url
/Media/Southampton-Clinical-Research/Downloads/Specialty-research-lead-advertisement-Surgery-May-2022.docx.pdf

Specialty research lead Hepatology advertisement May 2022.docx

Description
Clinical Research Specialty Lead - advertisement The National Institute for Health and Care Research (NIHR) is funded through the Department
Url
/Media/Southampton-Clinical-Research/Downloads/Specialty-research-lead-Hepatology-advertisement-May-2022.docx.pdf

Specialty research lead advertisement March 2022

Description
Clinical Research Specialty Lead - advertisement The National Institute for Health Research (NIHR) is funded through the Department of Health
Url
/Media/Southampton-Clinical-Research/Downloads/Specialty-research-lead-advertisement-March-2022.pdf

Erlotinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ERLOTINIB Regimen NSCLC - Erlotinib Indication Second line therapy of stage II
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Erlotinibver12.pdf

Crizotinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CRIZOTINIB This protocol may require funding Regimen NSCLC - Crizotinib Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CrizotinibVer1.pdf

Gemcitabine

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEMCITABINE Regimen NSCLC - Gemcitabine Indication Second line therapy of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gemcitabinever12.pdf

Gefitinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEFITINIB Regimen NSCLC - Gefitinib Indication Gefitinib is recommended as an option for the first-lin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gefitinibver13.pdf

Gemcitabine RT ver1

Description
Chemotherapy Protocol BLADDER CANCER GEMCITABINE RT Regimen Bladder – Gemcitabine RT Indication The treatment of muscle invasive bladder cancer WHO
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-RT-ver1.pdf

Gemcitabine (21day) ver1.1

Description
Chemotherapy Protocol BLADDER GEMCITABINE (21 day) Regimen Bladder-Gemcitabine Indication Locally advanced or metastatic urothelial cancer in patients unsuit
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-21day-ver1.1.pdf

Fluorouracil Mitomycin RT

Description
Chemotherapy Protocol BLADDER CANCER FLUOROURACIL-MITOMYCIN-RADIOTHERAPY Regimen • Bladder Cancer – Fluorouracil-Mitomycin-Radiotherapy Indication • Musc
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Fluorouracil-Mitomycin-RT.pdf
851 to 860 of 1000
Previous … 84 85 86 87 88 … Next